ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 180 filers reported holding ASCENDIS PHARMA A/S in Q1 2021. The put-call ratio across all filers is 1.02 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $74,725 | +38.4% | 798 | +31.9% | 0.00% | +100.0% |
| Q2 2023 | $53,996 | -60.6% | 605 | -52.6% | 0.00% | -75.0% |
| Q1 2023 | $136,920 | -16.4% | 1,277 | -4.8% | 0.00% | -20.0% |
| Q4 2022 | $163,776 | +23.1% | 1,341 | +3.8% | 0.01% | 0.0% |
| Q3 2022 | $133,000 | +79.7% | 1,292 | +63.1% | 0.01% | +66.7% |
| Q2 2022 | $74,000 | +138.7% | 792 | +201.1% | 0.00% | +200.0% |
| Q1 2022 | $31,000 | -64.8% | 263 | -59.9% | 0.00% | -66.7% |
| Q4 2021 | $88,000 | -16.2% | 656 | -0.3% | 0.00% | -25.0% |
| Q3 2021 | $105,000 | +66.7% | 658 | +36.5% | 0.00% | +33.3% |
| Q2 2021 | $63,000 | +37.0% | 482 | +35.0% | 0.00% | +50.0% |
| Q1 2021 | $46,000 | -2.1% | 357 | +26.1% | 0.00% | 0.0% |
| Q4 2020 | $47,000 | +38.2% | 283 | +27.5% | 0.00% | 0.0% |
| Q3 2020 | $34,000 | +209.1% | 222 | +196.0% | 0.00% | +100.0% |
| Q2 2020 | $11,000 | +175.0% | 75 | +134.4% | 0.00% | – |
| Q1 2020 | $4,000 | – | 32 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 5,865,338 | $978,221,000 | 13.68% |
| Vivo Capital, LLC | 1,797,745 | $299,828,000 | 13.38% |
| Sofinnova Investments, Inc. | 1,109,874 | $185,105,000 | 11.02% |
| Avoro Capital Advisors LLC | 1,800,000 | $300,204,000 | 5.17% |
| Eventide Asset Management | 1,704,148 | $284,218,000 | 4.36% |
| Stenahm Asset Managment Ltd | 29,000 | $4,837,000 | 4.07% |
| Ghost Tree Capital, LLC | 105,000 | $17,512,000 | 3.90% |
| Eversept Partners, LP | 187,043 | $31,195,032 | 3.66% |
| Spyglass Capital Management LLC | 701,594 | $117,012,000 | 3.59% |
| Q Global Advisors, LLC | 23,183 | $3,866,000 | 2.72% |